Creative Medical Technology Holdings, Inc. CELZ
Nov 4, 2026, 10:52 AM EST
- YTD
- -65.93%
- 1 year
- -76.57%
- Market cap
- 5.07M
- Revenue (ttm)
- 11.00K
- EPS (ttm)
- -2.07
- Shares out
- 1.75M
- Forward P/E
- -0.84
- YTD return
- -65.93%
- 1-year return
- -76.57%
- Volume
- 33.32K
- Avg volume
- 6.74M
- Open
- 0.6737
- Previous close
- 0.6735
- Day's range
- 0.6221 – 0.6737
- 52-week range
- 0.6006 – 4.72
- Price target
- 30.00 (+4393.0%)
- Earnings date
- Aug 9, 2024
2Y -2.8879 (-82.28%)
Key statistics
- Enterprise value
- -2.63M
- PEG ratio
- 0.00
- Price / sales
- 344.80
- Price / book
- 0.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.66M
- Total cash
- 6.26M
- Total debt
- 14.19K
- Return on equity
- -57.03%
- Short % of float
- 1.75%
- 50-day average
- 3.08
- 200-day average
- 3.82
Analyst view
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -0.63.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.85 | -0.75 | +0.10 | +11.76% |
| Aug 9, 2024 | Jun 1, 2024 | -0.84 | -1.11 | -0.27 | -32.14% |
| Aug 9, 2024 | Jun 1, 2024 | -0.84 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -1.15 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -1.15 | -0.73 | +0.42 | +36.52% |
| Mar 22, 2024 | Dec 1, 2023 | -1.13 | — | — | — |
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- creativemedicaltechnology.com
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Creative Medical Technology Highlights Ultrasome Data Showing 93% Response Rate, 65% Pain Reduction In Knee Osteoarthritis Study 
Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study 
Head to Head Analysis: Creative Medical Technology (NASDAQ:CELZ) versus Grifols (NASDAQ:GRFS) 
Creative Medical Technology Acquires 4M Additional BioDefense Stock For $200K Cash And 1M Shares, Raising Ownership To 80% 
Creative Medical Technology (NASDAQ:CELZ) & argenex (NASDAQ:ARGX) Head to Head Analysis 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - 12 Health Care Stocks Moving In Monday's After-Market Session
Creative Medical Technology Announces Filing Of New US Provisional Patent Application To Expand IP Protection Surrounding Ultrasome, Its Proprietary Cell-Free Regenerative Medicine Platform 
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
Your note
Sign in to keep a note on CELZ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| WARBINGTON TIMOTHY | Chief Executive Officer | Purchase | Jun 27, 2023 | 34,904 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Aaron Wealth Advisors | 1.12% | 19,570 | 42.47K | Sep 29, 2024 |
| Vanguard Group Inc | 1.01% | 17,629 | 38.25K | Sep 29, 2024 |
| Two Sigma Advisers, LP | 0.83% | 14,500 | 31.46K | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.75% | 13,106 | 28.44K | Sep 29, 2024 |
| UBS Group AG | 0.16% | 2,725 | 5.91K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.08% | 1,403 | 3.04K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.01% | 17,629 | 38.25K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.41% | 7,105 | 15.42K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 1,551 | 3.37K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 1,441 | 3.13K | Oct 30, 2024 |